Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified

Integra Lifesciences Holdings

(

IART

) as a strong and under the radar candidate. In addition to specific proprietary factors, Trade-Ideas identified Integra Lifesciences Holdings as such a stock due to the following factors:

  • IART has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $9.3 million.
  • IART is making at least a new 3-day high.
  • IART has a PE ratio of 58.8.
  • IART is mentioned 1.23 times per day on StockTwits.
  • IART has not yet been mentioned on StockTwits today.
  • IART is currently in the upper 20% of its 1-year range.
  • IART is in the upper 35% of its 20-day range.
  • IART is in the upper 45% of its 5-day range.
  • IART is currently trading above yesterday's high.

'Strong and Under the Radar' stocks tend to be worthwhile stocks to watch for a variety of factors including historical back testing and price action. Market technicians refer to such stocks as being in an accumulation phase before a mark-up and peak. Traders and hedge funds have frequently found that these types of stocks continue to build a solid price base and then ultimately spike higher and peak when others 'discover' how good the stock is performing. By leveraging the social discovery aspect of StockTwits we are highlighting stocks that don't currently receive much attention from retail investors, but we suspect may soon garner more attention.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in IART with the Ticky from Trade-Ideas. See the FREE profile for IART NOW at Trade-Ideas

More details on IART:

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neurosurgery; U.S. Extremities; U.S. IART has a PE ratio of 58.8. Currently there are 6 analysts that rate Integra Lifesciences Holdings a buy, no analysts rate it a sell, and 7 rate it a hold.

The average volume for Integra Lifesciences Holdings has been 167,800 shares per day over the past 30 days. Integra Lifesciences has a market cap of $2.0 billion and is part of the health care sector and health services industry. Shares are up 11.6% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Integra Lifesciences Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

Highlights from the ratings report include:

  • The revenue growth came in higher than the industry average of 1.0%. Since the same quarter one year prior, revenues rose by 14.2%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • INTEGRA LIFESCIENCES HLDGS has improved earnings per share by 15.6% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. We feel that this trend should continue. During the past fiscal year, INTEGRA LIFESCIENCES HLDGS turned its bottom line around by earning $1.04 versus -$0.81 in the prior year. This year, the market expects an improvement in earnings ($3.15 versus $1.04).
  • The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry average. The net income increased by 24.6% when compared to the same quarter one year prior, going from $13.77 million to $17.17 million.
  • Net operating cash flow has significantly increased by 77.47% to $20.76 million when compared to the same quarter last year. In addition, INTEGRA LIFESCIENCES HLDGS has also vastly surpassed the industry average cash flow growth rate of -7.23%.
  • The gross profit margin for INTEGRA LIFESCIENCES HLDGS is rather high; currently it is at 68.62%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, IART's net profit margin of 6.80% significantly trails the industry average.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null